Prophylactic sivelestat for esophagectomy and in-hospital mortality: a propensity score-matched analysis of claims database
- PMID: 30612210
- DOI: 10.1007/s00540-018-2602-9
Prophylactic sivelestat for esophagectomy and in-hospital mortality: a propensity score-matched analysis of claims database
Erratum in
-
Correction to: Prophylactic sivelestat for esophagectomy and in-hospital mortality: a propensity score-matched analysis of claims database.J Anesth. 2020 Feb;34(1):161-162. doi: 10.1007/s00540-019-02726-1. J Anesth. 2020. PMID: 31932943
Abstract
Purpose: Transthoracic esophagectomy is an invasive surgery, and the excessive surgical stress produces inflammatory cytokines, which provoke acute respiratory distress syndrome (ARDS). Sivelestat sodium hydrate-a selective neutrophil elastase inhibitor-is used to treat or prevent ARDS in patients undergoing esophagectomy, although clear evidence is lacking. We investigated the benefits and risk of prophylactic sivelestat.
Methods: This retrospective study used an administrative claims database in Japan. Adult patients who underwent transthoracic esophagectomy from 2010 to 2016 were identified and divided into a prophylactic sivelestat use group and a non-prophylactic use group that included both non-users and therapeutic users. The primary outcome was all-cause in-hospital mortality, and a secondary outcome included the proportion of ARDS. We used 1:1 propensity score matching. For sensitivity analyses, we conducted a 1:2 propensity score matching analysis and several analyses with various patient inclusion criteria.
Results: Of the 3391 patients with esophagectomy, 621 received prophylactic sivelestat. On unadjusted analysis, the sivelestat group had a higher proportion of in-hospital mortality (5.3% vs. 2.9%) compared with the control group. We created a matched cohort of 615 pairs, whose baseline characteristics were well balanced. On adjusted analysis using propensity score matching, prophylactic sivelestat administration was not associated with decreased in-hospital mortality [adjusted odds ratio (aOR) 1.65; 95% confidence interval (CI) 0.95-2.88], ARDS rate (aOR 1.25; 95% CI 0.49-3.17). The findings were also consistent with other sensitivity analyses.
Conclusion: Because mortality and postoperative complications were similar, our findings do not support prophylactic sivelestat administration for patients undergoing esophagectomy.
Keywords: Administrative claims; Esophagectomy; Mortality; Propensity score; Sivelestat.
Similar articles
-
Optimal period for the prophylactic administration of neutrophil elastase inhibitor for patients with esophageal cancer undergoing esophagectomy.World J Surg. 2011 Jul;35(7):1573-9. doi: 10.1007/s00268-011-1095-6. World J Surg. 2011. PMID: 21479682 Clinical Trial.
-
Preventive effect of sivelestat on postoperative respiratory disorders after thoracic esophagectomy.Surg Today. 2013 Apr;43(4):361-6. doi: 10.1007/s00595-013-0508-6. Epub 2013 Feb 15. Surg Today. 2013. PMID: 23412514
-
Prospective randomized controlled study on the effects of perioperative administration of a neutrophil elastase inhibitor to patients undergoing video-assisted thoracoscopic surgery for thoracic esophageal cancer.Dis Esophagus. 2010 May;23(4):329-39. doi: 10.1111/j.1442-2050.2009.01010.x. Epub 2009 Sep 25. Dis Esophagus. 2010. PMID: 19788440 Clinical Trial.
-
Neutrophil elastase inhibitor (sivelestat) may be a promising therapeutic option for management of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.J Clin Pharm Ther. 2020 Dec;45(6):1515-1519. doi: 10.1111/jcpt.13251. Epub 2020 Aug 28. J Clin Pharm Ther. 2020. PMID: 32860252 Review.
-
[Sivelestat sodium for aspiration-related acute lung injury: a review and analysis of published case reports].Masui. 2006 Jun;55(6):735-41. Masui. 2006. PMID: 16780088 Review. Japanese.
Cited by
-
Clinical epidemiology and pharmacoepidemiology studies with real-world databases.Proc Jpn Acad Ser B Phys Biol Sci. 2022;98(10):517-528. doi: 10.2183/pjab.98.026. Proc Jpn Acad Ser B Phys Biol Sci. 2022. PMID: 36504194 Free PMC article. Review.
-
Postoperative mortality in patients requiring home oxygen therapy: a nationwide hospital-based database study.J Anesth. 2025 Jun 30. doi: 10.1007/s00540-025-03532-8. Online ahead of print. J Anesth. 2025. PMID: 40586939
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical